Literature DB >> 26018883

Pulmonary emphysema induced by methylphenidate: experimental study.

Gabriel Victor Guimarães Rapello1, Andréia Antoniolli2, Daniel Martins Pereira1, Gilberto Facco3, Paulo Manuel Pêgo-Fernandes4, Rogério Pazetti5.   

Abstract

CONTEXT AND
OBJECTIVE: Methylphenidate is the most widely used drug for treating attention deficit hyperactivity disorder. However, it has important side effects, such as abdominal pain, insomnia, anorexia and loss of appetite, and also some cases of early severe emphysema after drug abuse have been reported. Our aim was to investigate the development of pulmonary emphysema in rats that were subjected to different doses of methylphenidate. DESIGN AND
SETTING: Experimental study carried out at the laboratory of a public university.
METHODS: Eighteen male Wistar rats were divided into three groups: control (0.9% saline solution); MP 0.8 (methylphenidate, 0.8 mg/kg); MP 1.2 (methylphenidate, 1.2 mg/kg). After 90 days of daily gavage, the animals were sacrificed and lung tissue samples were prepared for analysis on the mean alveolar diameter (Lm).
RESULTS: The Lm was greater in MP 0.8 (47.91 ± 3.13; P < 0.01) and MP 1.2 (46.36 ± 4.39; P < 0.05) than in the control group (40.00 ± 3.48).
CONCLUSION: Methylphenidate caused an increase in the alveolar diameter of rats, which was compatible with human pulmonary emphysema.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26018883     DOI: 10.1590/1516-3180.2014.8470910

Source DB:  PubMed          Journal:  Sao Paulo Med J        ISSN: 1516-3180            Impact factor:   1.044


  2 in total

1.  A case of recurrent pneumothorax related to oral methylphenidate.

Authors:  Viboon Boonsarngsuk; Thitiporn Suwatanapongched
Journal:  J Thorac Dis       Date:  2015-08       Impact factor: 2.895

2.  Acute or chronic pulmonary emphysema? Or both?-A contribution to the diagnosis of death due to violent asphyxiation in cases with pre-existing chronic emphysema.

Authors:  Giuseppe Gava; Simon B Eickhoff; Timm J Filler; Felix Mayer; Nina S Mahlke; Stefanie Ritz-Timme
Journal:  Int J Legal Med       Date:  2021-06-28       Impact factor: 2.686

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.